IZUMO family member 4Genealiases: C19orf36 · IMAGE:4215339
Q-omics provides the consensus-scored IZUMO4 profile across patient tissues and cancer cell-line models. IZUMO4 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, IZUMO4 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, IZUMO4 RNA expression shows 16,930 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, COAD, and THYM as cancer lineages where IZUMO4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IZUMO4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IZUMO4 survival associations across molecular data types. IZUMO4 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IZUMO4 RNA expression–survival associations across cancer types. High IZUMO4 expression shows unfavorable associations in KIRC, UCS, UVM and ACC, but favorable associations in BRCA and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for IZUMO4 RNA expression.
This table summarizes IZUMO4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for IZUMO4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IZUMO4 shows lower tumor expression in KICH, KIRP and KIRC and higher tumor expression in COAD, HNSC and BLCA. The COAD box plot shows higher IZUMO4 RNA expression in tumor versus normal tissue (log2 FC = +0.739, t-test p < 0.001).
This table shows molecular features associated with IZUMO4 in patient tissues and cancer cell lines. In patient samples, IZUMO4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, IZUMO4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and SOFT_TISSUE.
